Columbia Partners L L C Investment Management Raises Position in Becton, Dickinson and Company (BDX)

Columbia Partners L L C Investment Management increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,406 shares of the medical instruments supplier’s stock after purchasing an additional 756 shares during the period. Columbia Partners L L C Investment Management’s holdings in Becton, Dickinson and were worth $2,235,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of BDX. Guardian Life Insurance Co. of America raised its holdings in Becton, Dickinson and by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock valued at $150,000 after acquiring an additional 6 shares during the last quarter. Family Firm Inc. increased its holdings in shares of Becton, Dickinson and by 0.5% during the 2nd quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock worth $236,000 after buying an additional 6 shares during the last quarter. Northwest Quadrant Wealth Management LLC increased its holdings in shares of Becton, Dickinson and by 0.4% during the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock worth $332,000 after buying an additional 6 shares during the last quarter. Wellington Shields & Co. LLC increased its holdings in shares of Becton, Dickinson and by 0.3% during the 2nd quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock worth $496,000 after buying an additional 7 shares during the last quarter. Finally, Northstar Group Inc. increased its holdings in shares of Becton, Dickinson and by 0.3% during the 2nd quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock worth $584,000 after buying an additional 9 shares during the last quarter. Hedge funds and other institutional investors own 87.91% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE BDX) traded down $1.21 during trading on Monday, hitting $220.31. 719,600 shares of the stock were exchanged, compared to its average volume of 1,325,275. The firm has a market cap of $50,130.00, a price-to-earnings ratio of 23.22, a PEG ratio of 1.73 and a beta of 1.04. The company has a current ratio of 5.56, a quick ratio of 5.01 and a debt-to-equity ratio of 1.48. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $225.23.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. The business had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The company’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.12 EPS. equities analysts expect that Becton, Dickinson and Company will post 10.63 EPS for the current year.

A number of analysts have recently commented on the company. Barclays PLC restated an “equal weight” rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. BidaskClub downgraded Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research raised shares of Becton, Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $214.79.

COPYRIGHT VIOLATION WARNING: This article was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://sportsperspectives.com/2017/11/20/columbia-partners-l-l-c-investment-management-raises-position-in-becton-dickinson-and-company-bdx.html.

In related news, insider Gary M. Cohen sold 15,044 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $200.43, for a total transaction of $3,015,268.92. Following the sale, the insider now owns 95,270 shares in the company, valued at $19,094,966.10. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Stephen Sichak sold 11,787 shares of the stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the sale, the insider now owns 14,038 shares in the company, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,038 shares of company stock worth $9,480,225. Company insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply